AOD-9604: A Review of Published Preclinical Studies on This hGH Fragment

What Is AOD-9604?

AOD-9604 — short for Anti-Obesity Drug 9604 — is a synthetic 16-amino-acid peptide corresponding to residues 176–191 of human growth hormone (hGH), with an added tyrosine residue at the N-terminus that facilitates detection and stability. Researchers designed it to isolate the putative lipolytic domain of hGH while removing the region thought to be responsible for insulin-desensitizing effects. It has been investigated extensively in cell culture and rodent models, and it progressed into a limited set of human clinical trials before pharmaceutical development of the obesity indication was discontinued.

All research described in this article was conducted in laboratory or animal settings, or in early-phase clinical trials with specific endpoints. AOD-9604 is not approved by the FDA or any comparable regulatory body as a drug for human use. EVO Labs supplies it strictly as a research chemical for laboratory use only.

The Proposed Mechanisms: How Researchers Frame It

A central question in AOD-9604 research is how this fragment produces the metabolic changes observed in preclinical models. Several mechanisms have been proposed, though the relative contribution of each remains under investigation.

Beta-3 Adrenergic Receptor Activation

Early work by Heffernan and colleagues at Monash University suggested that AOD-9604 may stimulate beta-3 adrenergic receptors on adipocytes, the same receptor class targeted by several experimental anti-obesity compounds. In rodent adipose tissue preparations, AOD-9604 appeared to increase lipolysis — the breakdown of stored triglycerides into free fatty acids — in a receptor-dependent manner. Critically, this mechanism is distinct from the IGF-1 axis, which is the primary pathway through which intact hGH exerts anabolic effects.

Influence on Fat Oxidation Pathways

Additional preclinical studies have investigated whether AOD-9604 influences fatty acid oxidation downstream of lipolysis. In obese rodent models, researchers documented increases in resting energy expenditure in animals treated with AOD-9604 versus controls, an effect attributed in part to enhanced mitochondrial fatty acid oxidation rather than simply elevated lipolysis alone. These findings remain limited to animal models and have not been reproduced under rigorous human metabolic conditions.

Absence of IGF-1 Stimulation

One frequently cited characteristic in AOD-9604 research is that the peptide does not appear to stimulate IGF-1 production or activate the full growth hormone receptor complex in the same way intact hGH does. Because IGF-1 upregulation is associated with cell proliferation concerns at pharmacological doses, researchers have pointed to AOD-9604's apparent lack of IGF-1 effect as a potential safety differentiator in a research context. However, the long-term implications have not been established in humans.

"The C-terminal fragment of hGH retained lipolytic activity in vitro and in vivo while demonstrating a substantially reduced binding affinity at the primary growth hormone receptor compared with intact hGH." — Summary of findings reported in peer-reviewed characterization studies of the hGH 176–191 fragment.

Key Preclinical Research Findings

The bulk of evidence for AOD-9604 comes from rodent studies conducted primarily between the late 1990s and early 2010s. The table below summarizes the categories of findings and the model types from which they derive.

Research Area	Model Type	Observed Effect (Animal/Cell)	Human Evidence Status
Adipose tissue lipolysis	In vitro adipocytes; obese rodent models	Increased lipolysis vs. control	Largely absent; early-phase trials only
Body composition	Diet-induced obese mice; ob/ob mice	Reduced fat mass without muscle loss in treatment groups	Not established
Glucose metabolism	Rodent models	No significant insulin desensitization at studied doses	Limited Phase I/II data only
IGF-1 levels	In vitro; rodent serum assays	No significant IGF-1 elevation observed	Consistent with Phase I findings, not conclusive
Cartilage and joint tissue	Rabbit and rat osteoarthritis models	Researchers observed signals of cartilage remodeling activity	Not established

It is important to note that positive results in rodent obesity models frequently fail to translate to humans. The metabolic physiology of commonly used obese mouse strains (ob/ob, db/db, and high-fat-diet-induced models) differs substantially from human obesity, limiting the direct applicability of these findings. For a broader discussion of this challenge, see our primer on in vitro versus in vivo research.

Clinical Trial History: What Happened?

AOD-9604 is unusual among research peptides in that it did reach early-phase human clinical trials. The pharmaceutical company Metabolic Pharmaceuticals (later Calzada) advanced the compound through Phase I (safety and pharmacokinetics) and Phase IIa/b (dose-finding, short-term efficacy signals) trials focused on obesity treatment in overweight adults.

Phase I data suggested an acceptable short-term safety profile at the doses studied, with no significant changes in IGF-1, fasting glucose, or insulin resistance markers compared to placebo. However, the Phase II trials failed to demonstrate statistically significant weight loss versus placebo over the trial periods examined. Development as an obesity drug was subsequently discontinued.

Researchers have continued to explore the compound in other contexts — notably in cartilage and joint-tissue models — and academic interest in the fragment's receptor pharmacology remains active. Nonetheless, the current state of human evidence remains limited. The compound has not been approved for any indication by the FDA, EMA, or equivalent agencies.

AOD-9604 in Context: Comparisons With Related Research Areas

AOD-9604 research exists within a broader landscape of metabolic peptide science. The GLP-1 receptor agonist class — including semaglutide and its analogs — represents the area that has progressed furthest in clinical development for metabolic indications. For an overview of that trajectory, see our article on GLP-1 peptides in research. AOD-9604 operates through a distinct and structurally unrelated mechanism, though both research areas share the broader question of how peptide-based interventions might influence adipose tissue biology.

Within the growth hormone axis, AOD-9604 is distinct from intact recombinant hGH and from the GHRH analogs such as tesamorelin, which stimulate pituitary GH release rather than acting as GH fragments at peripheral receptors. Researchers studying metabolic peptides often compare these different points of intervention when designing experimental models. For context on the broader GH signaling axis, our overview of GH, GHRH, and GHRP distinctions provides useful background.

Analytical Considerations for Research Use

As with all synthetic peptides used in laboratory settings, the quality of AOD-9604 material directly affects the reliability of experimental results. Researchers should verify that any supply meets documented purity thresholds, is free of endotoxins that could confound cellular assays, and has been characterized by orthogonal analytical methods.

For AOD-9604, high-performance liquid chromatography (HPLC) is the standard technique for purity assessment. Mass spectrometry confirms molecular identity and can detect sequence errors or truncations that would not be apparent from HPLC alone. EVO Labs provides a Certificate of Analysis for each lot, covering HPLC purity, mass spec identity confirmation, and endotoxin levels. Researchers are encouraged to review lot-specific documentation before use. See also our overview of what peptide purity figures mean in practice.

Storage conditions for lyophilized AOD-9604 follow the general principles applicable to most synthetic peptides: protection from light and moisture, low-temperature storage, and avoidance of repeated freeze-thaw cycles of reconstituted solutions. For a detailed discussion, see our guide on peptide storage and stability.

Researchers sourcing AOD-9604 for metabolic studies can find available lots at EVO Labs AOD-9604 listings, with full lot documentation attached.

Current Limitations and Outstanding Research Questions

A candid assessment of the AOD-9604 literature reveals meaningful gaps that future research would need to address:

• Human translational gap: The majority of positive findings come from rodent models. Phase II clinical data did not replicate the magnitude of effect seen in animals, a pattern common across metabolic peptide research.
• Mechanistic resolution: While beta-3 adrenergic receptor involvement has been proposed, the full receptor pharmacology of AOD-9604 in human adipose tissue has not been comprehensively mapped.
• Long-term safety profile: Clinical trial durations were short. Long-term data in any species are sparse.
• Dose-response characterization: Preclinical dose-response curves do not map cleanly to human pharmacokinetics, and the Phase II trials used dose ranges derived from these imperfect translations.
• Tissue specificity: Whether the effects observed in adipose tissue models extend to other metabolically active tissues remains an open research question.

These limitations do not diminish the scientific interest in AOD-9604 as a research tool for understanding hGH fragment pharmacology. They do underscore why interpreting preclinical data carefully — and avoiding extrapolation to human use — is essential for responsible research conduct.